Gupta K <br/><br/>
151P Maintenance Therapy using Tyrosine Kinase Inhibitor (erlotinib) or Pemetrexed in metastatic/locally advanced in EGFR Mutation-Negative Lung Cancer:  Comparison of Results 

 -  2018 
 - 
<br/><br/> No Abstract 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Lung Cancer<br/>Pemetrexed<br/>EGFR Mutation-Negative